Posted by Michael Wonder on 08 May 2026
Korea begins insurance coverage for Novo Nordisk’s weekly growth hormone drug
6 May 2026 - Some children and adults in Korea with growth hormone deficiency can now receive Novo Nordisk’s once weekly treatment Sogroya through the country’s national health insurance system, lowering the cost of a medicine that may be needed for years.
Novo Nordisk Pharma Korea said Wednesday that coverage for Sogroya (somapacitan) began last Friday under a notice from the Ministry of Health and Welfare.
